Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2012
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics and Transaction Details
This filing reports a private placement financing transaction rather than periodic operating results. Key transaction metrics include:
- Shares Issued: 3,953,489 shares of common stock.
- Price Per Share: $2.15.
- Gross Proceeds: $8,500,001.
- Transaction Costs: $552,500 (placement agent fee to Jefferies & Company, Inc.) and $27,000 (legal fees/expenses for investors).
- Net Proceeds: $7,920,501.
- Anticipated Closing Date: October 2, 2012.
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt levels.
Material Changes and Use of Proceeds
The primary material change is the capital raise via private placement. The Company plans to utilize the net proceeds for:
- Research and development of drug candidates.
- Working capital.
- General corporate purposes.
Guidance, Risks, and Contingencies
Registration Obligations: The Company agreed to file a registration statement for the resale of shares within 45 days of the Closing Date and use best efforts to have it declared effective within 90 days (or 120 days if reviewed by the SEC).
Penalty for Delay: If the registration statement is not effective by the deadline, the Company must pay investors 1.5% of their aggregate purchase price for each 30-day period of delay, up to a maximum of 10%.
Investor Status: Shares were sold to "Accredited Investors" under Section 4(2) and Rule 506 of Regulation D exemptions.
Investor Verification Checklist
- Confirm the actual closing of the transaction on or around October 2, 2012.
- Verify the filing of the registration statement within 45 days of the closing date.
- Monitor the effectiveness date of the registration statement to assess potential penalty payments to investors.
- Review subsequent filings for updates on the deployment of the $7.92 million in net proceeds toward R&D.